Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,540,183
  • Shares Outstanding, K 47,728
  • Annual Sales, $ 28,630 K
  • Annual Income, $ -66,150 K
  • 60-Month Beta 2.18
  • Price/Sales 54.50
  • Price/Cash Flow N/A
  • Price/Book 4.67
Trade PTGX with:

Options Overview Details

View History
  • Implied Volatility 89.15%
  • Historical Volatility 50.67%
  • IV Percentile 77%
  • IV Rank 33.15%
  • IV High 134.11% on 09/17/21
  • IV Low 66.85% on 08/23/21
  • Put/Call Vol Ratio 0.50
  • Today's Volume 21
  • Volume Avg (30-Day) 571
  • Put/Call OI Ratio 951.83
  • Today's Open Interest 5,717
  • Open Int (30-Day) 1,508

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.79
  • Number of Estimates 6
  • High Estimate -0.70
  • Low Estimate -0.97
  • Prior Year -0.48
  • Growth Rate Est. (year over year) -64.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.75 +6.70%
on 12/02/21
38.11 -13.91%
on 11/15/21
-0.93 (-2.76%)
since 11/05/21
3-Month
12.80 +156.33%
on 09/20/21
50.54 -35.08%
on 09/07/21
-16.07 (-32.88%)
since 09/03/21
52-Week
12.80 +156.33%
on 09/20/21
50.54 -35.08%
on 09/07/21
+10.41 (+46.44%)
since 12/04/20

Most Recent Stories

More News
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -4.48% and 199.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the...

PTGX : 32.81 (+1.67%)
Protagonist Therapeutics: Q3 Earnings Snapshot

NEWARK, Calif. (AP) _ Protagonist Therapeutics Inc. (PTGX) on Wednesday reported a loss of $33.8 million in its third quarter.

PTGX : 32.81 (+1.67%)
New Strong Sell Stocks for October 14th

ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.

FMS : 31.52 (+3.62%)
OCUL : 6.18 (+0.32%)
BSET : 16.47 (+2.55%)
ARNC : 29.26 (+4.35%)
PTGX : 32.81 (+1.67%)
Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit

/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief...

PTGX : 32.81 (+1.67%)
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program

/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration (FDA)...

PTGX : 32.81 (+1.67%)
PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) (NASDAQ:...

PTGX : 32.81 (+1.67%)
Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) Investors

RADNOR, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders...

PTGX : 32.81 (+1.67%)
Protagonist, Schlumberger fall; Invesco, Thermo Fisher rise

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Friday:

LNC : 66.35 (+1.22%)
NCLH : 20.03 (+9.51%)
IVZ : 22.77 (+1.52%)
TMO : 622.25 (-2.18%)
FANG : 108.23 (+2.10%)
ENB.TO : 48.30 (+0.86%)
PTGX : 32.81 (+1.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 35.84
2nd Resistance Point 34.54
1st Resistance Point 33.67
Last Price 32.81
1st Support Level 31.50
2nd Support Level 30.20
3rd Support Level 29.33

See More

52-Week High 50.54
Fibonacci 61.8% 36.12
Last Price 32.81
Fibonacci 50% 31.67
Fibonacci 38.2% 27.22
52-Week Low 12.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar